AGS-004 / CoImmune - LARVOL DELTA

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. (PubMed, Sci Rep) - "In contrast to previous clinical data, AGS-004 did not induce HIV-specific immune responses greater than those measured at baseline. More efficacious antiviral immune interventions, perhaps paired with more effective latency reversal, must be developed to clear persistent HIV infection."

IO Biomarker • Journal

The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection (IAS-HIV 2019) - "The combination of AGS-004 and VOR was safe and well tolerated. Few participants showed a decrease in rca-HIV RNA, but no substantial impact on the replication competent reservoir was measured. Surprisingly, the induction of HIV-specific immune responses by AGS-004 was marginal and inconsistent across all participants."

IO Biomarker

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. (PubMed, AIDS Res Hum Retroviruses) - "However, greater expansion of CD28(-)/CCR7(-)/CD45RA(-) CD8(+) effector T cell responses correlated with a longer time to viral rebound. AGS-004 may be a useful tool to augment immune responses in the setting of latency reversal and eradication strategies."

Clinical • Journal